Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

<p>Abstract</p> <p>Background</p> <p>In patients with chronic hepatitis C virus (HCV) genotype 2 or 3, 24 weeks' treatment with pegylated interferon alfa (PEG-IFN-alpha) and ribavirin induces a sustained virological response (SVR) in almost 80% of cases. Evidence suggests that a similar response rate may be obtained with shorter treatment periods, especially in patients with a rapid virological response (RVR). The aim of this study was to compare the efficacy of 12 or 24 weeks of treatment in patients with chronic HCV genotype 2 or 3 and to identify patients suitable for 12 weeks treatment.</p> <p>Methods</p> <p>Two hundred and ten patients received PEG-IFN-alpha-2a (180 ug/week) and ribavirin (800-1200 mg/day) for 4 weeks. Patients with a RVR (HCV RNA not detectable) were randomized (1:1) to either 12 (group A1) or 24 (group A2) weeks of combination therapy. Patients without a RVR continued with 24-weeks' combination therapy (group B). HCV RNA was monitored at weeks 4, 8, 12, and 24, and at week 24 post-treatment.</p> <p>Results</p> <p>At study end, end of treatment response (ETR) was observed in 62 (86%) patients of group A1 and in 55 (77%) patients of group A2 (p < 0.05) Relapse rate was 3% each in groups A1 and A2, and 6% in group B. Among patients with a HCVRNA test 24 weeks after the end of treatment, SVR was observed in 60 (83%) of group A1 patients and in 53 (75%) of group A2 patients. Rapid virological response, low baseline HCV RNA levels, elevated alanine aminotransferase levels and low fibrosis score, were the strongest covariates associated with SVR, independent of HCV genotype. No baseline characteristic was associated with relapse.</p> <p>Conclusion</p> <p>In HCV patients with genotype 2 or 3, 12-week combination therapy is as efficacious as 24-week therapy and several independent covariates were predictive of SVR.</p> <p>Trial registration</p> <p>Trial number ISRCTN29259563</p

Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma

Background and rationale of the study. Effect of Long-term nucleoside/nucleotide (NUC) on hepatocellular carcinoma (HCC) incidence in a population of HBeAg-negative genotype D patients has not been adequately studied in real-life cohorts. Our aim was to evaluate the impact of liver fibrosis and other variables on HCC incidence in this population of patients. Of 745 patients with chronic hepatitis B (CHB), 306 HBeAg-negative genotype D were selected and included in this study. All patients received treatment with NUC for at least 18 months. Patients with CHB or compensated cirrhosis were included. Patients with HCC diagnosed before or during the first 18 months of NUC therapy were excluded. Results. HCC was diagnosed in 2 CHB patients (1.0%) and 23 cirrhosis patients (20%) (OR = 24.41, 95% CI 5.40 < OR < 153.2; p < 0.0001). Multivariate analysis revealed that HCC risk was independently associated with age ≥ 60 years (OR = 6.45, 95% CI 1.22 to 34.0; p = 0.02) and liver cirrhosis (OR = 12.1, 95% CI 1.39 to 106.2; p = 0.02), but not with virological response (VR), and previous resistance to NUC, or rescue therapy. Multivariate analysis in cirrhosis patients revealed that only age ≥ 60 years was an independent risk factor associated with HCC (p = 0.003). Conclusions. Liver cirrhosis and age ≥ 60 years are the stronger risk factors for HCC in genotype D HBeAgnegative patients. Previous resistance to NUC in patients that achieved a VR after rescue therapy was not a predictive factor regarding HCC. VR does not appear to significantly reduce the overall incidence of HCC when a patient has already progressed to liver cirrhosis

Culture commune de l'évaluation au cycle 3 Réseau REP+ Miramaris

International audience> Objectifs du projet • Produire des connaissances sur l'activité des professionnels en matière de pratiques d'évaluation, en Éducation Prioritaire • Développer le pouvoir d'agir des professionnels en charge de la conception, de la mise en oeuvre de la continuité éducative dans un cycle inter-degrés > Démarche Modalités de coopération entre les acteurs des écoles et du collège du réseau REP+ et les enseignants chercheurs de l'ESPE • Cerner des objets de réflexion collective pour co-construire des modalités de travail à travers la compréhension des pratiques existantes, l'identification des points d'appui et résistances et la conception/appropriation d'outils et dispositifs communs • Interventions centrées sur les pratiques effectives : Observations et enregistrements filmés dans les classes suivies d'instructions au sosie et/ou d'entretiens d'auto-confrontation simples et/ou croisées • Communication des principaux éléments soumis à discussion au sein de ce collecti

Culture commune de l'évaluation au cycle 3 Réseau REP+ Miramaris

International audience> Objectifs du projet • Produire des connaissances sur l'activité des professionnels en matière de pratiques d'évaluation, en Éducation Prioritaire • Développer le pouvoir d'agir des professionnels en charge de la conception, de la mise en oeuvre de la continuité éducative dans un cycle inter-degrés > Démarche Modalités de coopération entre les acteurs des écoles et du collège du réseau REP+ et les enseignants chercheurs de l'ESPE • Cerner des objets de réflexion collective pour co-construire des modalités de travail à travers la compréhension des pratiques existantes, l'identification des points d'appui et résistances et la conception/appropriation d'outils et dispositifs communs • Interventions centrées sur les pratiques effectives : Observations et enregistrements filmés dans les classes suivies d'instructions au sosie et/ou d'entretiens d'auto-confrontation simples et/ou croisées • Communication des principaux éléments soumis à discussion au sein de ce collecti

Culture commune de l'évaluation au cycle 3 Réseau REP+ Miramaris

International audience> Objectifs du projet • Produire des connaissances sur l'activité des professionnels en matière de pratiques d'évaluation, en Éducation Prioritaire • Développer le pouvoir d'agir des professionnels en charge de la conception, de la mise en oeuvre de la continuité éducative dans un cycle inter-degrés > Démarche Modalités de coopération entre les acteurs des écoles et du collège du réseau REP+ et les enseignants chercheurs de l'ESPE • Cerner des objets de réflexion collective pour co-construire des modalités de travail à travers la compréhension des pratiques existantes, l'identification des points d'appui et résistances et la conception/appropriation d'outils et dispositifs communs • Interventions centrées sur les pratiques effectives : Observations et enregistrements filmés dans les classes suivies d'instructions au sosie et/ou d'entretiens d'auto-confrontation simples et/ou croisées • Communication des principaux éléments soumis à discussion au sein de ce collecti

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Objectives: The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and clinical or virologic resistance to LAM. Furthermore, we evaluated in these selected patients the clinical covariates associated with a sustained virologic response. Methods: Data from adult outpatients aged &gt; 18 years with chronic HBV infection and clinical or virologic resistance to LAM were used in this retrospective, Multicenter, nonrandomized, open-label study. Patients were selected if they received ADV 10 mg PO QD + LAM 100 mg QD PO or ADV 10 mg PO QD as monotherapy for 24 to 32 months between June 2003 and July 2006. End points were the proportions of patients who achieved virologic response (undetectable HBV-DNA [&lt; 3.3 log(10) copies/mL]) and biochemical response (normalization [&lt; 40 IU/L] of alanine aminotransferase [ALT]), and the proportions in whom resistance to ADV (rebound serum HBV-DNA &gt; 1 log(10) copies/mL compared with on-treatment nadir, as confirmed on molecular analysis) was found. HBV-DNA and ALT levels were checked every month during the first 3 months of treatment and every 3 months thereafter until 28 months. Data from each center were stored in a centralized database and analyzed by a blinded independent investigator. Results: Data from 70 patients were included (48 men, 22 women; median age, 51 years; ADV + LAM, 36 patients; ADV monotherapy, 34). The median duration of the pharmacologic treatment in the 2 groups of patients was 28 months (range, 24-32 months). By month 3, virologic response was achieved in 30 patients (83%) in the ADV + LAM group and in 26 patients (76%) in the ADV monotherapy group. At 12 months, virologic response was achieved in 5 additional patients in the ADV + LAM group and 2 additional patients in the ADV monotherapy group. Biochemical response was found to be time dependent: in the 2 groups, the rates of biochemical response were, respectively, 56% and 54% at month 3, 80% and 71% at month 6, and 96% and 79% at month 12, persisting up to the end of the study period. The rates of clinical resistance to ADV were 3% with ADV + LAM and 18% with ADV monotherapy (with a 6% rate of resistance due to rtA 181 mutation in the monotherapy group). Logistic regression analysis found that pretreatment levels of HBV-DNA &lt; 5 log(10) copies/mL, ALT levels &gt; 150 IU/L, an inflammation score &gt; 7, and a fibrosis score &lt; 2 were the strongest covariates independently associated with a sustained virologic response in both groups of patients. No adverse events were reported in any of the patients. Conclusion: ADV, administered in combination with LAM or as monotherapy, appeared to be effective in this small, selected group of HBeAg-negative patients with clinical or virologic resistance to LAM, especially in those with low pretreatment HBV-DNA levels, high ALT levels, and low fibrosis scores